3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
49
Carcinoma, Renal Cell
30
Neoplasm Metastasis
18
Neoplasms
15
Kidney Neoplasms
14
Neuroendocrine Tumors
11
Carcinoma, Neuroendocrine
9
Prostatic Neoplasms
7
Melanoma
7
Triple Negative Breast Neoplasms
6
Thyroid Neoplasms
6
Sarcoma
6
Meningioma
6
Lymphoma
6
Glioma
6
Endometrial Neoplasms
6
Tuberous Sclerosis
5
Stomach Neoplasms
5
Recurrence
5
Lymphoma, Mantle-Cell
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Liver Neoplasms
4
Carcinoma, Islet Cell
4
Astrocytoma
4
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
Everolimus
×
Clear all
NCT06472388
2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled